NCT00438009View on ClinicalTrials.gov

A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03)

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 16, 2007

Primary Completion Date

August 28, 2009

Study Completion Date

August 28, 2009

Conditions
Stage IV Melanoma
Interventions
DRUG

Coxsackievirus A21

Two doses of drug, separated by 48 hours

Trial Locations (1)

Unknown

Princess Alexandra Hospital, Brisbane

Sponsors

Lead Sponsor

Viralytics
All Listed Sponsors
lead

Viralytics

INDUSTRY

NCT00438009 - A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03) | Biotech Hunter | Biotech Hunter